References
- Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000–8.
- Weber U, Lambert RG, Ostergaard M, Hodler J, Pedersen SJ, Maksymowych WP.. The diagnostic utility of magnetic resonance imaging in spondylarthritis: an international multicenter evaluation of one hundred eighty-seven subjects. Arthritis Rheum 2010;62:3048–58.
- Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, . The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777–83.
- van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, . 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905–8.
- Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G, . Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011;70:590–6.
- Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, . Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomized placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815–22.
- Landewe R, Rudwaleit M, van der Heijde D, Dougados M, Maksymowych WP, Braun J, . Effect of certolizumab pegol on signs and symptoms of axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: 24-week results of RAPID-AXSPA study. Ann Rheum Dis 2013;72(Suppl s3):86: Abstract OP0106.
- Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index for evaluating TNF blockers in clinical practice: 5-year observational data from Southern Sweden. Arthritis Rheum 2006;54:600–6.
- Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
- Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Williams M, Stone M, . Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:703–9.
- Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P.. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 2010;62:1362–9.
- Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 14 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010;69:2002–8.
- Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, . Tumor necrosis factor α inhibition in radiographic and non-radiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum 2013;65:3096–106.
- Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, . Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18–24.
- van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, . ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811–18.